# The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006, Regulation 29: Amendment of Schedule 3 to the principal Regulations


In Schedule 3 to the principal Regulations (particulars and documents that must accompany an application for an ethics committee opinion, a request for authorisation, a notice of amendment and a notification of the conclusion of a trial)—
(a) in Part 2 (request for authorisation), in paragraph 1, in sub-paragraph (b), for “the European Community” substitute “an EEA State”;
(b) in Part 3 (notice of amendment)—
(i) in paragraph 1, in sub-paragraph (b), for “the European Community” substitute “an EEA State”, and
(ii) in paragraph 2, in sub-paragraph (b), for “the number” substitute “any number”; and
(c) in Part 4 (notification of conclusion of a clinical trial)—
(i) in paragraph 1, in sub-paragraph (b), for “the European Community” substitute “an EEA State”, and
(ii) in paragraph 2, in sub-paragraph (b), for “the number” substitute “any number”.

---
Source: https://www.legislation.gov.uk/uksi/2006/1928/regulation/29 (the official version)
Page: https://openlegislation.uk/medicines-for-human-use-clinical-trials-amendment-regulations-2006/regulation-29
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.